Published in Drug Metab Dispos on August 01, 1999
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Impact of OATP transporters on pharmacokinetics. Br J Pharmacol (2009) 2.97
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol (2012) 1.74
Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov (2010) 1.73
Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol (2006) 1.71
Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev (2010) 1.52
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers. Arch Dermatol Res (2011) 1.43
Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest (2010) 1.37
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol (2002) 1.28
Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos (2011) 1.24
Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol (2010) 1.20
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem (2012) 1.18
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol (2005) 1.15
Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology (2009) 1.14
Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend (2009) 1.14
Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx (2005) 1.11
Dietary effects on drug metabolism and transport. Clin Pharmacokinet (2003) 1.11
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther (2008) 1.05
Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin Pharmacol Toxicol (2009) 1.04
Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2012) 1.04
Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx (2005) 1.03
Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther (2009) 1.03
Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol (2006) 1.03
Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther (2012) 1.01
Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol (2011) 1.01
Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci (2011) 0.98
Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol (2008) 0.97
Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos (2013) 0.94
Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol (2009) 0.91
Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol (2011) 0.91
Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology (2012) 0.91
Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. Br J Clin Pharmacol (2008) 0.91
Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol (2011) 0.91
Pharmacology of antihistamines. Indian J Dermatol (2013) 0.91
Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics (2009) 0.90
Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. Drug Metab Dispos (2013) 0.89
Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos (2008) 0.88
Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol (2009) 0.87
Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth Analg (2009) 0.87
Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos (2007) 0.87
The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol (2008) 0.86
Quantification of the transporter substrate fexofenadine in cell lysates by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2011) 0.85
Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol (2006) 0.85
The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br J Clin Pharmacol (2003) 0.85
Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol (2011) 0.84
Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration. Drug Metab Dispos (2008) 0.84
A recursive-partitioning model for blood-brain barrier permeation. J Comput Aided Mol Des (2005) 0.84
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med (2012) 0.83
Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol (2009) 0.83
Hepatocellular transport proteins and their role in liver disease. World J Gastroenterol (2001) 0.82
Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.81
Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function. Pharm Res (2009) 0.81
Effects of grapefruit juice on the pharmacokinetics of acebutolol. Br J Clin Pharmacol (2005) 0.81
Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clin Pharmacokinet (2016) 0.81
Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol (2012) 0.81
Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol (2007) 0.80
Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.79
Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. Eur J Clin Pharmacol (2010) 0.79
P-glycoprotein function in the elderly. Eur J Clin Pharmacol (2004) 0.78
Plasma membrane transporters in modern liver pharmacology. Scientifica (Cairo) (2012) 0.78
Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions. AAPS J (2009) 0.78
Specific safety and tolerability considerations in the use of anticonvulsant medications in children. Drug Healthc Patient Saf (2012) 0.78
Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Br J Pharmacol (2014) 0.78
Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers. Eur J Clin Pharmacol (2014) 0.76
A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect". J Clin Pharmacol (2013) 0.76
Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma. J Pharm Biomed Anal (2011) 0.76
Organic anion transporting polypeptides and organic cation transporter 1 contribute to the cellular uptake of the flavonoid quercetin. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.76
Validation of the use of nonnaive surgically catheterized rats for pharmacokinetics studies. J Am Assoc Lab Anim Sci (2008) 0.75
Fexofenadine hydrochloride in the treatment of allergic disease: a review. J Asthma Allergy (2008) 0.75
Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease. Br J Pharmacol (2017) 0.75
Drug-phytochemical interactions. Inflammopharmacology (2003) 0.75
Small molecule membrane transporters in the mammalian podocyte: a pathogenic and therapeutic target. Int J Mol Sci (2014) 0.75
No major effects of vitamin D3 (1,25 dihydroxyvitamin D3) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers. Eur J Clin Pharmacol (2016) 0.75
A Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation. Mol Pharm (2017) 0.75
Uptake and metabolism of sulphated steroids by the blood-brain barrier in the adult male rat. J Neurochem (2017) 0.75
The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. Eur J Clin Pharmacol (2016) 0.75
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone. J Pharmacol Exp Ther (2017) 0.75
Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96
Quality-of-life outcomes in men treated for localized prostate cancer. JAMA (1995) 4.69
The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest (1975) 4.65
The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care (1998) 4.34
Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med (1981) 3.98
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Development of a brief screening instrument for detecting depressive disorders. Med Care (1988) 3.37
Why do symptomatic patients delay obtaining care for tuberculosis? Am J Respir Crit Care Med (1998) 3.30
Do physicians preach what they practice? A study of physicians' health habits and counseling practices. JAMA (1984) 3.05
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05
Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol (2001) 2.86
Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther (2001) 2.79
The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med (2001) 2.74
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69
Managed care and capitation in California: how do physicians at financial risk control their own utilization? Ann Intern Med (1995) 2.64
Does fear of immigration authorities deter tuberculosis patients from seeking care? West J Med (1994) 2.61
Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther (2007) 2.52
In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol (1998) 2.45
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem (2001) 2.42
Health status, job satisfaction, job stress, and life satisfaction among academic and clinical faculty. JAMA (1985) 2.37
Quality of care for patients with rheumatoid arthritis. JAMA (2000) 2.30
Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med (1989) 2.29
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics (2001) 2.29
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
How satisfying is the practice of internal medicine? A national survey. Ann Intern Med (1991) 2.20
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther (1984) 2.19
The counseling practices of internists. Ann Intern Med (1991) 2.02
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation (1999) 2.01
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem (1985) 1.97
The effect of gender and training of residents on satisfaction ratings by patients. J Med Educ (1984) 1.89
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos (2000) 1.87
The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos (1996) 1.86
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996) 1.85
Effect of physician specialty on use of necessary coronary angiography. J Am Coll Cardiol (1995) 1.83
Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest (1974) 1.74
Agreement between face-to-face and telephone-administered versions of the depression section of the NIMH Diagnostic Interview Schedule. J Psychiatr Res (1988) 1.71
Primary care physicians' satisfaction with quality of care in California capitated medical groups. JAMA (1997) 1.68
Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med (1976) 1.68
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem (2001) 1.67
Internal medicine patients' expectations for care during office visits. J Gen Intern Med (1994) 1.66
Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther (1979) 1.62
Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol (1978) 1.60
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.57
Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther (1979) 1.55
An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation (1994) 1.52
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics (2001) 1.50
The practices of general and subspecialty internists in counseling about smoking and exercise. Am J Public Health (1986) 1.49
Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology (1978) 1.48
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther (2000) 1.48
A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis (2006) 1.46
Sympathetic activation enhances QT prolongation by quinidine. J Cardiovasc Electrophysiol (2001) 1.45
Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med (1982) 1.43
Outcomes of specialized and traditional AIDS counseling programs for impoverished women of color. Res Nurs Health (1993) 1.43
CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther (2000) 1.42
Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther (1978) 1.39
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 1.38
Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther (1985) 1.38
AIDS-related knowledge, perceptions, and behaviors among impoverished minority women. Am J Public Health (1993) 1.36
Biological determinants of propranolol disposition in man. Clin Pharmacol Ther (1978) 1.35
Altered hepatic blood flow and drug disposition. Clin Pharmacokinet (1976) 1.34
A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther (2003) 1.34
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33
Type of social support among homeless women: its impact on psychosocial resources, health and health behaviors, and use of health services. Nurs Res (2000) 1.33
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics (1999) 1.33
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther (1999) 1.32
Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol (2011) 1.31
Reliability of homeless women's reports: concordance between hair assay and self report of cocaine use. Nurs Res (2001) 1.30
Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry (1984) 1.29
Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics (2001) 1.28
Tuberculosis skin testing among homeless adults. J Gen Intern Med (1997) 1.28
The initial effects of the prospective payment system on nursing home patients. Am J Public Health (1987) 1.28
The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet (1979) 1.28
Clearance approaches in pharmacology. Pharmacol Rev (1987) 1.27
Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther (1987) 1.25
Sheltered versus nonsheltered homeless women differences in health, behavior, victimization, and utilization of care. J Gen Intern Med (2000) 1.23
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation (1987) 1.22
Normal metabolism of morphine in cirrhosis. Gastroenterology (1981) 1.22
The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther (1974) 1.22
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21
Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther (1974) 1.21
Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther (2007) 1.20
Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry (1995) 1.20
Substance abuse and mental health status of homeless and domiciled low-income users of a medical clinic. Hosp Community Psychiatry (1990) 1.19
Health habits and coping behaviors among practicing physicians. West J Med (1986) 1.18
Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clin Pharmacol Ther (1979) 1.16
Drug disposition and liver disease. Drug Metab Rev (1975) 1.14
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res (1999) 1.14